ストックスクリーナーアプリを入手
30.49
6.80%
1.94
プレマーケット:
30.99
0.50
+1.64%
前日終値:
$28.55
開ける：
$33.745
24時間の取引高:
8.58M
Relative Volume:
2.70
時価総額：
$3.45B
収益：
-
当期純損益:
$-237.39M
株価収益率:
-14.39
EPS:
-2.1183
ネットキャッシュフロー:
$-224.58M
1週間 パフォーマンス:
+15.98%
1か月 パフォーマンス:
-4.00%
6か月 パフォーマンス:
-23.51%
1年 パフォーマンス:
+3.99%
1日の値動き範囲:
$30.18
$34.38
1週間の範囲:
$26.89
$34.38
52週間の値動き範囲:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
30.49 | 3.23B | 0 | -237.39M | -224.58M | -2.1183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-29 | 開始されました | Canaccord Genuity | Buy |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 開始されました | Goldman | Neutral |
| 2025-02-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-07 | 開始されました | Citigroup | Neutral |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-11-22 | 開始されました | B. Riley Securities | Buy |
| 2024-11-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-11 | 開始されました | JP Morgan | Overweight |
| 2024-06-27 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-07 | 開始されました | Jefferies | Buy |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
Viking Therapeutics Advances VK2735 Toward Phase 3 After FDA Feedback - AD HOC NEWS
What is HC Wainwright's Forecast for VKTX Q4 Earnings? - MarketBeat
Is Viking Therapeutics (VKTX) Pricing Reflecting Recent Drug Development Progress? - simplywall.st
Viking Therapeutics' VK2735 Sees Strong Demand Amid Novo Nordisk Launch - Intellectia AI
Pipeline Momentum Boosts Viking Therapeutics as Phase 3 Timeline Accelerates - AD HOC NEWS
Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress - Yahoo Finance
Viking Therapeutics stock rating reiterated at Buy by Laidlaw - Investing.com Nigeria
Viking Therapeutics Bets Big on Obesity Breakthroughs - TipRanks
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN
Viking Therapeutics (NASDAQ:VKTX) Shares Gap UpTime to Buy? - MarketBeat
Viking Therapeutics pushes GLP-1/GIP obesity pill to phase 3 - TechTarget
Viking to push oral GLP-1/GIP drug into phase III obesity trial - BioWorld MedTech
Viking Therapeutics Stock Soars: What's Driving The Momentum? - Benzinga
Stock Movers: Equinix, Crocs, Viking Therapeutics - Bloomberg.com
Viking Therapeutics stock price target lowered to $118 by Raymond James By Investing.com - Investing.com Canada
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $99 - 富途牛牛
Viking Therapeutics (VKTX) Shares Rise on Promising Obesity Drug Updates - GuruFocus
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript - Insider Monkey
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates - Yahoo Finance
Viking Therapeutics stock price target lowered to $118 by Raymond James - Investing.com
Viking Therapeutics rises after Q4 updates (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics Advances Oral Obesity Drug Toward Final Clinical Trials - AD HOC NEWS
Morgan Stanley Trims Price Target on Viking Therapeutics to $99 From $102, Keeps Overweight Rating - marketscreener.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Viking Therapeutics stock soars on plans for Phase 3 obesity drug trial - Investing.com
Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus - Bez Kabli
Viking Therapeutics, Inc. (VKTX) shares surged 11.7% in pre-market trading after the company announced plans to advance its oral obesity treatment drug to late-stage trials. - Bitget
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Viking Therapeutics plans to advance oral obesity drug to late-stage testing - whbl.com
Viking Therapeutics Q4 2025 Earnings Call Highlights - Intellectia AI
Viking Therapeutics (VKTX) Advances Obesity Pipeline Amidst Fina - GuruFocus
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Inc (VKTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs - GuruFocus
Viking (VKTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Viking Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Viking Therapeutics stock climbs after Q4 report: Details - MSN
Viking Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast By Investing.com - Investing.com India
Earnings call transcript: Viking Therapeutics Q4 2025 misses EPS forecast - Investing.com
How Viking’s Q4 2025 Earnings and VK2735 Weight-Loss Updates Will Impact Viking Therapeutics (VKTX) Investors - simplywall.st
Viking Therapeutics, Inc. SEC 10-K Report - TradingView
VKTX: Late-stage clinical progress and strong cash reserves position the company for future growth - TradingView
Viking Therapeutics (VKTX) Reports Q4 EPS Miss and Advances Obes - GuruFocus
Viking (VKTX) Advances Obesity Treatment with Key Developments - GuruFocus
Viking Therapeutics Q4 Loss Widens - marketscreener.com
Viking Therapeutics plans to advance oral obesity drug to late-stage trial - marketscreener.com
Earnings Flash (VKTX) Viking Therapeutics, Inc. Reports Q4 Revenue $0K - marketscreener.com
Viking Therapeutics Stock Climbs After Q4 Report: Details - Benzinga
Viking Therapeutics (NASDAQ:VKTX) Announces Earnings Results - MarketBeat
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):